1. "2021"
Formats
  1. Journal Article (2507)
  2. Meeting Abstract (1731)
  3. Review (604)
  4. Editorial (358)
  5. Book Section (123)
  6. Correspondence (107)
  7. Guidelines (103)
  8. Research Letter (91)
  9. Miscellaneous (52)
  10. Conference Paper (34)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2534)
  2. Solid Tumor Oncology Division (1517)
  3. Sloan Kettering Institute Postdocs (1176)
  4. GSK Faculty (1088)
  5. Surgery (954)
  6. Survivorship Research (922)

More Groups

People
  1. Alexander Drilon (76)
  2. Miguel-Angel Perales (68)
  3. Sergio Giralt (66)
  4. Robert Motzer (65)
  5. Marc Ladanyi (62)
  6. Monica Morrow (57)

More People

Years
  1. 2021 (5712)
Publications
  1. Journal of Clinical Oncology (471)
  2. Blood (252)
  3. Annals of Oncology (148)
  4. Cancer Research (145)
  5. International Journal of Radiation Oncology, Biology, Physics (145)
  6. Journal of Thoracic Oncology (101)

More Publications

Publishers
  1. Elsevier Inc. (723)
  2. American Society of Clinical Oncology (522)
  3. Springer (381)
  4. Oxford University Press (360)
  5. Nature Publishing Group (344)
  6. American Association for Cancer Research (297)

More Publishers

Results (5712)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Alpha particle radiobiology and the treatment of prostate adenocarcinoma
    Meeting Abstract

    Mello, B. P.; Revskaya, E.; Scheinberg, D. A.; McDevitt, M. R.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • MSH2 is necessary for temozolomide-induced ATR activation in MGMT-methylated cancers
    Meeting Abstract

    Ganesa, S.; Sule, A. D.; Jackson, C. B.; Sundaram, R. K.; Bindra, R. S.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Activation of STING in response to partial-tumor radiation exposure
    Meeting Abstract

    Mathieu, M.; Nepali, P. R.; Budhu, S.; Powell, S. N.; Humm, J. L.; Deasy, J. O.; Haimovitz-Friedman, A.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer
    Meeting Abstract

    Oh, D. Y.; Park, J. O.; Kindler, H. L.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Arnold, D.; Reinacker-Schick, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Colorectal cancer presentation and survival outcomes in Nigeria: A prospective multi-centre cohort study of 543 patients
    Meeting Abstract

    Aderibigbe, A.; Dare, A.; Knapp, G.; Alatise, O.; Kingham, T. P.
    Cancer Epidemiology Biomarkers and Prevention (2021)

    Fulltext@MSK | Save
  • Self-assembling and disassembling bispecific antibody platform for pretargeted radioimmunotherapy against GPA33 in a xenograft model of colorectal peritoneal carcinomatosis
    Meeting Abstract

    Chung, S.; Wang, M.; Veach, D.; Cheal, S.; Burnes Vargas, D.; Seo, S. H.; Punzalan, B.; Santich, B.; Guo, H. F.; Xu, H.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Integration of genomic and clinical data from 25,000 patients identifies molecular determinants of metastatic potential and organotropisms
    Meeting Abstract

    Nguyen, B.; Fong, C.; DiNatale, R.; Luthra, A.; Nandakumar, S.; Walch, H.; Chatila, W. K.; Rajanna, A.; Solit, D. B.; Berger, M. F.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial
    Meeting Abstract

    Morise, M.; Sakai, H.; Veillon, R.; Le, X.; Felip, E.; Garassino, M. C.; Cortot, A. B.; Smit, E.; Park, K.; Griesinger, F.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy and safety with selpercatinib in patients with RET fusion plus NSCLC: Analysis by last prior systemic therapy
    Meeting Abstract

    Goto, K.; Gautschi, O.; Drilon, A.; Tan, D. S. W.; Oxnard, G. R.; McCoach, C.; Park, K.; Casal, G. A.; de Braud, F.; French, P.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC
    Meeting Abstract

    Hayashi, H.; Yu, H. A.; Baik, C.; Gold, K.; Johnson, M. L.; Koczywas, M.; Murakami, H.; Nishio, M.; Steuer, C.; Su, W. C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save